You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Novavax, SII get emergency use authorisation for Covid vaccine in Indonesia

The vaccine will be manufactured by SII in India and marketed by it in Indonesia under the brand name Covovax, Novavax Inc said in a statement

Topics
Coronavirus | Coronavirus Vaccine | Serum Institute of India

Press Trust of India  |  New Delhi 

Coronavirus vaccine, Covid-19 vaccines

Biotechnology firm Novavax Inc and its partner on Monday said they have received the first emergency use authorisation (EUA) for Novavax's COVID-19 vaccine, in Indonesia.

The vaccine will be manufactured by (SII) in India and marketed by it in Indonesia under the brand name Covovax, Novavax Inc said in a statement.

"The National Agency of Drug and Food Control of the Republic of Indonesia, or Badan Peng was Obat dan Makanan (Badan POM), has granted emergency use authorisation (EUA) for Novavax' recombinant nanoparticle protein-based COVID-19 vaccine with Matrix-M adjuvant," it added.

Initial shipments into Indonesia are expected to begin imminently, the statement said.

"The first authorisation of Novavax' COVID-19 vaccine exemplifies our commitment to equitable global access and will fill a vital need for Indonesia, which despite being the fourth most populous nation on earth, continues to work to procure sufficient vaccine for its population," Novavax President and Chief Executive Officer Stanley C Erck said.

This also marks the first regulatory authorisation worldwide of a protein-based COVID-19 vaccine based on Phase-III clinical data demonstrating efficacy and a favourable safety profile, he added.

On the development, CEO Adar Poonawalla said that access to supply of a safe and highly effective vaccine, coupled with the ease of its distribution, should be a critical enabler to help Indonesia control the current outbreak.

"We continue to work with urgency to ensure that the first protein-based COVID-19 vaccine option in Indonesia is available for all awaiting its arrival," he added.

Novavax and SII have already filed for authorisation of Novavax' COVID-19 vaccine in India and the Philippines, as well as for emergency use listing (EUL) with the World Health Organization (WHO), the statement said.

Recently, Novavax also completed rolling submissions for authorisation of the Novavax vaccine with regulatory agencies in the UK, European Union, Canada and Australia, it added.

"Novavax expects to submit additional regulatory filings for its vaccine around the world as well as an additional supplemental filing for its vaccine for EUL with the WHO, shortly. Novavax expects to submit its complete package to the US FDA by the end of the year," the statement said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, November 01 2021. 21:36 IST
RECOMMENDED FOR YOU